Drugs / TE-8105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06471530 | Jul 2024 → Jan 2025 | — | Immunwork, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-08-10 | Immunwork, Inc. | Results TE-8105 Featured in Tech Times, Highlighting Fatty Acid Bundle Engineering and Biweekly Dosing Potential immunwork.com ↗
In the Phase 1/2a study, TE-8105 demonstrated a mean plasma half-life of approximately 120 hours (about five days), supporting further evaluation of a biweekly subcutaneous dosing strategy. |
| 2026-08-04 | Immunwork, Inc. | Results Immunwork’s Long-Acting GLP-1 Candidate TE-8105 Receives Dual International Recognition immunwork.com ↗
The publication, entitled “ First-in-human study of a long-acting GLP-1 receptor agonist (TE-8105) in overweight or obese adults without type 2 diabetes mellitus ,” reports the clinical pharmacology and safety findings of TE-8105. |
| 2026-03-19 | Immunwork, Inc. | Results Our Latest Research Published in International Journal of Pharmaceutics immunwork.com ↗
We are thrilled to announce the publication of our paper, entitled “Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice”, has been published in the latest issue of the International Journal of Pharmaceutics. |
| 2025-12-08 | Immunwork, Inc. | Results Immunwork Announces Positive Phase 1/2a Results for TE-8105, a Long-Acting GLP-1 RA, Demonstrating Favorable Safety, Tolerability, and Weight-loss Potential immunwork.com ↗
Conducted in Australia, the study demonstrated that TE-8105 is safe, well tolerated, and exhibits clear weight-loss potential, with only mild adverse events observed. |
| 2025-03-06 | Immunwork, Inc. | Results Our latest research result is published in J. Med. Chem. immunwork.com ↗
the research team successfully developed the long-acting GLP-1 receptor agonist TE-8105, which demonstrates superior efficacy compared to Semaglutide. |
| 2024-07-30 | Immunwork, Inc. | Results Two ultra-long acting drugs receive promising news! Phase 1 clinical trials are expected to be completed next year! immunwork.com ↗
Both drugs have undergone initial dosing in low-dose subjects, showing good tolerance and no significant side effects. |
All press releases naming this drug 8 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TE-8105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06471530 ↗ |
| Route | Subcutaneous | “injection via subcutaneous (SC) injection into the abdomen” NCT06471530 ↗ |